KCM
SRPT icon

Kennedy Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Kennedy Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,847
Closed -$756K – 666
2025
Q1 		$756K Sell
11,847
-17,610
-60% -$1.85M 0.02% 550
2024
Q4 		$3.58M Buy
29,457
+3,776
+15% +$463K 0.08% 392
2024
Q3 		$3.21M Buy
+25,681
New +$3.55M 0.07% 407
2023
Q2 		– Sell
-3,495
Closed -$482K – 694
2023
Q1 		$482K Buy
+3,495
New +$453K 0.01% 562

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Kennedy Capital Management's SRPT Position: Q2 2025 in Review

Kennedy Capital Management sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 11,847 shares — an estimated $756K sold.

Kennedy Capital Management first reported a position in SRPT in Q1 2023 and held it in 4 quarters. The position peaked at $3.58M in Q4 2024. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

  • Kennedy Capital Management reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Kennedy Capital Management sold 11,847 Sarepta Therapeutics shares in Q2 2025, an estimated $756K.
  • Kennedy Capital Management first reported a position in Sarepta Therapeutics in Q1 2023 and held it in 4 quarters.
  • Kennedy Capital Management's Sarepta Therapeutics position peaked at $3.58M in Q4 2024.
  • 362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Kennedy Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.